ArticleJournal of virology2019
Atovaquone Inhibits Arbovirus Replication through the Depletion of Intracellular Nucleotides.
Article in Journal of virology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 42 citations in OpenAlex.
- Structure-based pharmacophore modeling and DFT studies of Indian Ocean-derived red algal compounds as PI3Kα inhibitors.Molecular diversity · 2024Article
- FDA approved drugs with antiviral activity against SARS-CoV-2: From structure-based repurposing to host-specific mechanisms.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2023Article
- High-Throughput Quantitative Glycomics Enabled by 12-plex Isobaric Multiplex Labeling Reagents for Carbonyl-Containing Compound (SUGAR) Tags.Journal of proteome research · 2023Article
- An open-label randomized controlled trial of leflunomide in patients with acute SARS-CoV-2 omicron variant infection.Frontiers in medicine · 2023Article
- Anti-Alphaviral Alkaloids: Focus on Some Isoquinolines, Indoles and Quinolizidines.Molecules (Basel, Switzerland) · 2022Review
- Antiviral Activity of Approved Antibacterial, Antifungal, Antiprotozoal and Anthelmintic Drugs: Chances for Drug Repurposing for Antiviral Drug Discovery.Journal of experimental pharmacology · 2022Review
- Guanosine inhibits hepatitis C virus replication and increases indel frequencies, associated with altered intracellular nucleotide pools.PLoS pathogens · 2022Article
- Article
- Indole alkaloids inhibit zika and chikungunya virus infection in different cell lines.BMC complementary medicine and therapies · 2021Article
- Antivirals against the Chikungunya Virus.Viruses · 2021Review
- Therapeutic Options for Coronavirus Disease 2019 (COVID-19): Where Are We Now?Current infectious disease reports · 2021Review
- Mefloquine, a Potent Anti-severe Acute Respiratory Syndrome-Related Coronavirus 2 (SARS-CoV-2) Drug as an Entry InhibitorFrontiers in microbiology · 2021Article
- COVID-19: Vaccine Delivery System, Drug Repurposing and Application of Molecular Modeling Approach.Drug design, development and therapy · 2021Review
- The Antimalarial Compound Atovaquone Inhibits Zika and Dengue Virus Infection by Blocking E Protein-Mediated Membrane Fusion.Viruses · 2020Article
- Small-Molecule Inhibitors of Chikungunya Virus: Mechanisms of Action and Antiviral Drug Resistance.Antimicrobial agents and chemotherapy · 2020Review
- Potent inhibition of tumour cell proliferation and immunoregulatory function by mitochondria-targeted atovaquone.Scientific reports · 2020Article
- Antiviral Strategies against Arthritogenic Alphaviruses.Microorganisms · 2020Review
- Potential repurposed SARS-CoV-2 (COVID-19) infection drugs.RSC advances · 2020Review
- Mapping the evolutionary landscape of Zika virus infection in immunocompromised mice.Virus evolution · 2020Article
- Regioselective convergent synthesis of 2-arylidene thiazolo[3,2-RSC advances · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Arthropod-borne viruses represent a significant public health threat worldwide, yet there are few antiviral therapies or prophylaxes targeting these pathogens. In particular, the development of novel antivirals for high-risk populations such as pregnant women is essential to prevent devastating disease such as that which was experienced with the recent outbreak of Zika virus (ZIKV) in the Americas. One potential avenue to identify new and pregnancy-acceptable antiviral compounds is to repurpose well-known and widely used FDA-approved drugs. In this study, we addressed the antiviral role of atovaquone, an FDA Pregnancy Category C drug and pyrimidine biosynthesis inhibitor used for the prevention and treatment of parasitic infections. We found that atovaquone was able to inhibit ZIKV and chikungunya virus virion production in human cells and that this antiviral effect occurred early during infection at the initial steps of viral RNA replication. Moreover, we were able to complement viral replication and virion production with the addition of exogenous pyrimidine nucleosides, indicating that atovaquone functions through the inhibition of the pyrimidine biosynthesis pathway to inhibit viral replication. Finally, using an
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.